NICE has opened a second public consultation on the use of belimumab (Benlysta) as a treatment for patients with systemic lupus erythematosus. In the new draft guidance, belimumab is not recommended, within its licensed indication, as an add-on therapy in adults with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy. This is the second draft guidance consultation in the appraisal of belimumab, as an appeal on final draft guidance was upheld in 2012.  For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsBelimumabSystemicLupusErythematosus.jsp